Bristol-Myers Squibb Cites Positive Data in Retreatment of Hepatitis B Using Baraclude
April 16, 2007
On Friday, Bristol-Myers Squibb reported its drug Baraclude was effective in retreating patients with recurrent levels of hepatitis B virus. In a cohort study, the drug maker said 93 percent of patients who had previously taken Baraclude but whose treatment was interrupted were able to suppress the virus by using the drug again for 48 weeks. The Food and Drug Administration approved Baraclude in 2005.
Antiretroviral Therapy Access Increases in Developing Countries, Hundreds of Thousands of Child Deaths Preventable, U.N. Report Says
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.